ArticleStatistics in medicine2026
A Functional Joint Model for Survival and Multivariate Sparse Functional Data in Multi-Cohort Alzheimer's Disease Study.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Functional Joint Model for Survival and Multivariate Sparse Functional Data in Multi-Cohort Alzheimer's Disease Study.Statistics in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We develop an integrative joint model for multivariate sparse functional and survival data to analyze Alzheimer's disease (AD) across multiple studies. To address missing-by-design outcomes in multi-cohort studies, our approach extends the multivariate functional mixed model (MFMM), which integrates longitudinal outcomes to extract shared disease progression trajectories and links these outcomes to time-to-event data through a parsimonious survival model. This framework balances flexibility and interpretability by modeling shared progression trajectories while accommodating cohort-specific mean functions and survival parameters. For efficient estimation, we incorporate penalized splines into an EM algorithm. Application to three AD cohorts demonstrates the model's ability to capture disease trajectories and account for inter-cohort variability. Simulation studies confirm its robustness and accuracy, highlighting its value in advancing the understanding of AD progression and supporting clinical decision-making in multi-cohort settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.